Shares of CareDx (NASDAQ: CDNA), a leading precision medicine company specializing in transplant diagnostics, surged 7.55% on November 6, 2024, following the company's better-than-expected third-quarter 2024 financial results.
For the quarter, CareDx reported revenue of $82.9 million, representing a 23% year-over-year increase and exceeding analyst estimates by 2.7%. The company's net loss narrowed significantly by 69% compared to the same period last year, and its earnings per share loss of $0.14 beat expectations of a $0.43 loss.
Looking ahead, CareDx forecasts revenue growth of 12% per annum on average over the next three years, although this lags the broader US biotechnology industry's forecast of 21% growth. Nevertheless, the company's strong financial performance and positive outlook for continued expansion and profitability improvements appear to have fueled investor confidence, driving the stock's soaring movement on November 6.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。